Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.
Guardant Health (NASDAQ:GH) Coverage Initiated by Analysts at Bank of America
Fairfield Current - Nov 6, 2018
October's winners & losers: Growth IPOs still fly high
Nasdaq - Nov 1, 2018
Guardant Health, Inc. (GH) moves -0.38% below SMA-50
Nasdaq Place (press release) - Oct 31, 2018
These 14 startups — endorsed by the seed-stage investment firm Pear — just hit the fundraising trail
TechCrunch - Oct 28, 2018
Cancer blood-testing company Guardant Health files for IPO
MarketWatch - Sep 6, 2018
Guardant Silent on TMB Plans as Study Adds Evidence for Immunotherapy Prediction in Blood
GenomeWeb - Jul 31, 2018
Liquid Biopsy Controversy Rages On
Forbes - Jul 19, 2018
Guardant Health Appoints Leena Das-Young to Lead Efforts to Develop Liquid Biopsy Products for Early-Stage Cancer Applications
Jul 12, 2018
Guardant Health to Present 29 Abstracts at ASCO Advancing the Science of Liquid Biopsy Across Multiple Indications ...
PR Newswire (press release) - May 23, 2018
Guardant Health Publishes Extensive Validation of Guardant360® Assay Comprising Largest-Published Blood-Tissue ...
PR Newswire (press release) - Apr 26, 2018
Guardant Health Inc Market Analysis 2018 to 2025
Healthcare Trends - Apr 7, 2018
Guardant Health Applauds Medicare For Final Decision Benefiting Advanced Cancer Patients
PR Newswire (press release) - Mar 19, 2018
Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of Lung Cancer Trial
PR Newswire (press release) - Mar 13, 2018
The Guardant360® Assay Receives Expedited Access Pathway Designation for Breakthrough Devices from FDA
PR Newswire (press release) - Feb 15, 2018
Liquid Biopsy Market Growing Rates of Cancer Coupled with ...
Medgadget (blog) - Feb 12, 2018
Global Liquid Biopsy Market Projections 2018- Guardant Health, RainDanceTechnologies and Biocartis
Incredible News 24 - Jan 22, 2018
Guardant Health Expands Support for the Development of the GuardantOMNI™ Assay Through New Agreement with ...
PR Newswire (press release) - Nov 16, 2017
Guardant Health Database Reveals Potential of Targeted Therapy Combinations to Treat Advanced Lung Cancer
PR Newswire (press release) - Nov 6, 2017
Liquid Biopsy Market Size Is Anticipated To Reach $5.96 Billion By ...
Medgadget (blog) - Oct 17, 2017
Liquid biopsies predict response to immunotherapy
Healio - Oct 5, 2017
Guardant Health Receives Investigational Device Exemption Approval from the FDA to Support Merck KGaA ...
PR Newswire (press release) - Sep 26, 2017
DNA start-ups attract cash from venture funds
Financial Times - Sep 24, 2017
Guardant Health Sues Foundation Medicine for False Advertising
GenomeWeb - Jun 22, 2017
Guardant Health, Foundation Medicine to Participate in Cure-One N1 Registry
GenomeWeb - Jun 5, 2017
Cure-One™ Announces Partnership with Guardant Health
PR Newswire (press release) - Jun 3, 2017
New York Approves Guardant Health's Liquid Biopsy Test
GenomeWeb - May 24, 2017
Guardant Health Announces Draft Medicare Local Coverage Determination for the Guardant360 Assay
PR Newswire (press release) - May 18, 2017
Guardant Health introduces new initiative to sequence tumor DNA of one million cancer patients
News-Medical.net - May 15, 2017
*Based on Preferred Stock Price, Guardant Health does not have a stock symbol since it is currently private and is yet to have an IPO.
Virgin Hyperloop One,
Dollar Shave Club,
Asana, Blink Health,
Farmers Business Network,
- Helmy Eltoukhy, Chief Executive Officer
- Derek Bertocci, Chief Financial Officer
- Michael Wiley, Chief Legal Officer
- Richard Lanman, Chief Medical Officer
- AmirAli Talasaz, COO & President
- Sandra Finley, VP of Marketing
- Stanley Welle, Head of Sales
- Darya Chudova, VP of Bioinformatics
- Daniel Simon, Vice President, Pharma Business Development
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Guardant Health or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
EQUITYZEN and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.